CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • December 30th, 2020 • Yumanity Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledDecember 30th, 2020 Company Industry JurisdictionTHIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of December 22, 2020 (this “Agreement”), is entered into by and among Proteostasis Therapeutics, Inc., a Delaware corporation (“PTI”), Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as the initial representative, agent and attorney-in-fact of the Holders of CVRs (the “CVR Holders’ Representative”).
CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • August 24th, 2020 • Proteostasis Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledAugust 24th, 2020 Company Industry JurisdictionTHIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [●], 2020 (this “Agreement”), is entered into by and among Proteostasis Therapeutics, Inc., a Delaware corporation (“PTI”), Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as the initial representative, agent and attorney-in-fact of the Holders of CVRs (the “CVR Holders’ Representative”).